Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results
Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi’s…
Press Release
Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor
SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE American: CLDI or…
Press Release
Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform
SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE American: CLDI or…
Press Release
Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board
Former NIH/National Cancer Institute neuro-oncology leader adds in-depth government healthcare agency expertise to Calidi SAN…
Press Release
Calidi to Effect Reverse Stock Split
Calidi common stock expected to begin trading on a 1-for-10 split adjusted basis on July…
Press Release
Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors
SAN DIEGO, CALIF. — June 27, 2024 – Calidi Biotherapeutics, Inc. (NYSE American: CLDI or…
Press Release
Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13
SAN DIEGO–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology…
Press Release
Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors
Calidi’s best-in-class, novel systemic targeted virotherapy program (RTNova) aims to provide a feasible solution to…
Press Release
Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting
– NeuroNova (CLD-101) Phase 1 update highlights enrollment progress, safety and feasibility in delivering up…
Press Release
Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
SAN DIEGO–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology…
Press Release
Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results
Three upcoming posters, including an update from ongoing Phase 1 trial of Calidi’s CLD-101 program,…
Press Release
Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
SAN DIEGO–(BUSINESS WIRE)– Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing…
Press Release
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering
SAN DIEGO–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing…
Press Release
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering
SAN DIEGO–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing…
Press Release
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024
Data supports CLD-101 and CLD-201’s first-in-class use of stem cells to protect and potentiate antitumor…
Press Release
Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer
City of Hope was awarded $5.3 million from CIRM to develop a treatment for metastatic…
Press Release
Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference
– Preclinical models have demonstrated the ability to resist oncolytic virus inactivation by human serum…
Press Release
Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board
Antonio Chiocca, M.D., Ph.D., Chair, Department of Neurosurgery at Brigham and Women’s Hospital, Co-Director, Institute…
Press Release
Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit
SAN DIEGO–(December 13, 2023)–Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company…
Press Release
Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of Directors
SAN DIEGO–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing…
